摘要
目的:观察右佐匹克隆治疗失眠症的临床疗效与不良反应。方法:140例失眠症患者随机分为治疗组(70)例和对照组(70)例。治疗组患者每晚睡前服用右佐匹克隆3~6 mg;对照组患者每晚睡前服用劳拉西泮1~2 mg。连续服用4周。在服药前、服药后1周末、第2周末、第4周末应用"阿森斯失眠量表(ASDR)"评定患者睡眠障碍的改善情况。应用"副反应量表(TESS)"评定药物的不良反应。结果:ASDR评分在治疗结束时,两组较基线均显著降低(P〈0.01);研究组和对照组的有效率分别为81.4%和78.6%,两组比较无显著性差异(P〉0.05)。但研究组患者的起效时间较对照组快,总的睡眠质量更好。研究组不良反应发生率低于对照组(P〈0.01)。结论:右佐匹克隆治疗失眠症患者疗效好,且不良反应少,是一种治疗失眠症安全而有效的新药。
Objective: To evaluate the efficacy and safety of dexzopiclone in the treatment of insomnia.Methods: Totally 140 patients with insomnia were randomly divided into two groups,and received dexzopiclone(3~6 mg,n=70) or lorazepam(1~2 mg,n=70) daily for 4 weeks.The scores of Asens sleep dysfunction rating(ASDR) and treatment emergent symptoms scale(TESS) were determined before and 1,2 and 4 weeks after treatment.Results: Compared with the baseline,sleeping quality was significantly improved in both groups with effective rates of 81.4%(dexzopiclone group) and 78.6%(lorazepam group),respectively,4 weeks after treatment.There were no significant differences in the effective rates of two groups(P0.05).However,dexzopiclone showed faster efficacy and lower incidence of adverse events than lorazepam(P0.01).Conclusion: Dexzopiclone is effective and safe in the treatment of insomnia.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2011年第14期1305-1307,1313,共4页
Chinese Journal of New Drugs